CD274 and non-small cell lung carcinoma: Pembrolizumab has been shown to have significantly greater efficacy than platinum doublet chemotherapy as a first‐line treatment for advanced non‐small cell lung cancer (NSCLC) patients with programmed death‐ligand 1 (PD‐L1) expression tumor proportion score (TPS) ≥50%.1